Check-Cap to present at the 2nd Annual Disruptive Growth and Healthcare Conference on February 15
Press releases may be edited for formatting or style | February 08, 2017
Rad Oncology
ISFIYA, Israel, February 8, 2017 / Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, announced today that Bill Densel, CEO of Check-Cap will be presenting at the 2nd Annual Disruptive Growth & Healthcare Conference on Wednesday, February 15 at 9:30AM EST.
To access a live webcast of this presentation, please visit http://ir.check-cap.com/. A replay will be available following the presentation.
Colorectal cancer is the second leading cause of cancer death in the U.S., with an estimated 134,000 diagnoses and 49,000 deaths in 2016. Despite compelling evidence that screening can detect colorectal cancer and precancerous polyps, nearly one-third of the recommended adult population has never been screened. The C-Scan® system was designed to improve the patient experience by eliminating the features of existing screening methods, such as bowel preparation, invasive procedure, and sedation, that pose a barrier to test completion.
For those interested in attending, please visit www.DisruptNYC.com for more information.
About Check-Cap Ltd.
Check-Cap is a clinical-stage medical diagnostics company developing C-Scan®, the first capsule-based system for preparation-free, colorectal cancer screening.
Utilizing innovative ultra-low dose X-ray and wireless communication technologies, the capsule generates information on the contours of the inside of the colon as it passes naturally. This information is used to create a 3D map of the colon, which allows physicians to look for polyps and other abnormalities. Designed to improve the patient experience and increase the willingness of individuals to participate in recommended colorectal cancer screening, C-Scan removes many frequently-cited barriers, such as laxative bowel preparation, invasiveness and sedation. The C-Scan system is currently not cleared for marketing in any jurisdiction.
|
|
|
You Must Be Logged In To Post A Comment
|
